Jondoeuk, why would autologous dendritic cell vaccines prepared from recurrent GBM tumors be utilized to treat all the recurrent GBM patients in a trial (both arms), if previously, identically prepared autologous dendritic cell vaccines derived from primary GBM tumors, failed to demonstrate efficacy in the primary GBM patients?